NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effects of Obesity on Autophagy and mTORC1 Signalling in Skeletal Muscle
Effects of Obesity on Autophagy and mTORC1 Signalling in Skeletal Muscle

NCT07774676

RecruitingN/A

Sponsor: University of Birmingham

Conditions: Overweight and Obese Adults

Interventions: Skeletal muscle biopsy, venous blood sampling, Protein-Rich Beverage, Single-leg resistance exercise, Dual-Energy X-ray Absorptiometry (DEXA) Scan

Countries: United Kingdom

It is well known that individuals living with overweight or obesity are not able to activate skeletal muscle growth processes to the same extent as lean individuals following activities such as weightlifting (resistance exercise) or protein ingestion. However, the underlying cell signalling pathways which may be regulating these impairments are not fully understood. This study aims to understand if skeletal muscle signalling responses to resistance exercise and protein intake differ between lean individuals and those living with overweight or obesity. The investigators will recruit a cohort of lean individuals and a cohort of individuals living with overweight/obesity who will undertake a bout of single-leg resistance exercise and consume a protein-rich drink. Before and after this, muscle samples will be obtained from each leg of participants at different timepoints to understand the effects of exercise and feeding combined (exercised leg) and feeding alone (rested leg) on different cellular processes which regulate muscle growth. This will allow the investigators to understand if their are specific pathways within skeletal muscle which could be targeted in future interventions to overcome impaired protein metabolism in those living with overweight/obesity.

Eligibility overview

Sex: ALL

Age: 18 Years to 45 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Age - 18-45yrs
* BMI - 18.5-24.9kg/m2 OR \>28kg/m2 (self-declaration, or calculated by research team based on height and weight)
* Weight Stable i.e. no change in weight of more than 5% in previous 6 months
* Meeting UK Physical activity guidelines (150 mins moderate or 75 mins vigorous activity/wk)
* Not involved in structured exercise training in previous 6 months
* No other diagnosed metabolic or neuromuscular conditions (self-declaration)

Exclusion Criteria:

* Currently using anti-diabetes medication (insulin, metformin, sulphonylureas, meglitinides, thiazolidinediones, DPP- 4 inhibitors, GLP-1 inhibitors).
* Currently taking cholesterol lowering medications (statins)
* Currently engaged in active weight loss programmes or using weight loss medication
* Chronic kidney disease (moderate to severe reduction in kidney function), defined as eGFR \<30 ml/min/1.73m2 identified by self declaration.
* Pregnant or breast feeding
* Currently using anti-coagulation medication
* Hypothyroidism
* Type 1 diabetes
* Current or recent weakness/injury to either leg that may affect muscle function or ability to exercise
* Current gastrointestinal issue/condition that may affect digestion and absorption of protein drink
* Individuals who follow a vegan diet or have intolerance/allergies to Whey protein.
* Previous adverse reaction to local anaethetic (lidocaine or marcaine).
Locations (1)
  • Birmingham, United Kingdom